Search 

Our strategy is to selectively collaborate with leading companies with the resources and capabilities to assist us in developing and commercializing some of our product candidates, particularly in target indications for which our collaborator has significant expertise or that involve large primary care markets. We generally seek co-promotion or co-commercialization rights in alliances.

We have a collaboration with AstraZeneca focused in cognitive disorders that includes AZD-3480 and AZD-1446.  We have the option to co-promote  certain compounds licensed under our cognitive disorders agreement to selected specialist physicians in the US.

 We are currently interested in exploring alliances or collaborations for:

• TC-5619, which is in on-going Phase 2 trials in negative symptoms of schizophrenia and ADHD predominantly inattentive subtype; • TC-6499, which in a Phase 2a study showed encouraging potential to enhance GI motility relevant to treating GI/GU disorders such as diabetic gastroparesis and IBS-C/CIC; and • Targacept’s Parkinson’s disease/levodopa-induced dyskinesia program to exploit NNR Therapeutics for symptomatic treatment and disease modification.

We are receptive to evaluating clinical-stage CNS, GI/GU or Orphan opportunities to complement our pipeline.

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is an international specialty pharmaceutical company that develops, and manufactures pharmaceutical products. Teikoku focuses its efforts in three therapeutic areas; Pain Management, CNS and Oncology.  Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, distributed by Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe. Our core technology platforms include; passive and active transdermal delivery systems as well as injectables. We are currently actively seeking to in-license/acquire later stage product for the US, Europe and Japan.

TherapeuticsMD (TXMD) is a publicly traded Women’s Health company located in South Florida.

TXMD currently has a national sales force calling on OB-GYNs in the US and a strong pipeline of late stage HRT products. We are currently pursuing in-licensing opportunities within the Women’s Health space and considering out-licensing International partners for our 3 late stage HRT products.

Theravance, Inc. - Medicines that Make A Difference®

Summary Products / Services / Technologies

Collaborations and Clients

About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. TH-302 is the lead and only clinical stage product in our pipeline.  For additional information, please visit our website (www.thresholdpharm.com).

About TH-302
TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark of many cancer indications. Areas of low oxygen levels (hypoxia) within tissues are common in many solid tumors due to insufficient blood vessel growth.

TH-302 has been investigated in over 600 patients in Phase 1/2 clinical trials to date in a broad spectrum of tumor types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs. Threshold has several additional ongoing clinical trials, the most advanced of which is a Phase 3 pivotal study evaluating TH-302 in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma. More recently, Threshold completed a 215 patient randomized Phase 2 in combination with gemcitabine vs gemcitabine alone in advanced pancreatic cancer.  The initial results we presented at AACR earlier this year and a follow up will be presented at ESMO in late September.

In February 2012, Threshold signed a global agreement with Merck KGaA, Darmstadt, Germany, to co-develop and co-commercialize TH-302.

Clinical stage biotech with a solution for gene/protein delviery to cancer cells.

Tocagen is a private biopharma developing a unique retroviral replicating vector (RRV) platform that can efficiently delivery a gene or protein of choice selectively to cancer cells.

·         A fundamental challenge in oncology is to selectively deliver active agents to cancer cells while sparing healthy tissue.  We believe we may have found a solution.
·         Unlike oncolytic viruses, RRVs are unique because they replicate by budding-off from the host cancer cell which allows "stealth" spread through cancer tissue without being cleared by the immune system.
·         Our RRV system is capable of delivering genes such as those that code for prodrug activator enzymes, shRNA, or therapeutic proteins.
·         Our lead RRV product candidate, Toca 511, delivers a prodrug activator gene, cytosine deaminase (CD), selectively to cancer cells.
·         Toca 511 is used in combination with Toca FC, a proprietary formulation of 5-FC, that is converted in the presence of CD in infected cancer cells to 5-FU.
·         To date, Toca 511 & 5-FC has been dosed in 36 patients with high grade glioma in two ascending dose Phase I trials.
·         In addition to a promising safety and efficacy profile in patients, we have also accumulated data in patients supporting the anticipated mechanism of action for this approach
·         Now that we have clinical validation for our technology platform, we are interested in partnership discussions e.g. building new RRV constructs for the delivery of a gene or protein of interest to the partner.

More details about our technology can be found at www.tocagen.com and more information about our clinical trials can be found here: http://clinicaltrials.gov/ct2/results?term=tocagen

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment is complete in a multinational Phase 2b trial evaluating TZP-102 given once daily in diabetic patients with gastroparesis; top-line data are expected by year-end 2012. Tranzyme has initiated a second Phase 2b trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis; top-line data are expected in the first half of 2013. By leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.

We have successfully completed our first Phase 3 clinical trial for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.

 Trius is headquartered in San Diego, California.